PE20070165A1 - Formulacion de comprension directa que comprende un inhibidor de dipeptidil-peptidasa iv y una glitazona - Google Patents
Formulacion de comprension directa que comprende un inhibidor de dipeptidil-peptidasa iv y una glitazonaInfo
- Publication number
- PE20070165A1 PE20070165A1 PE2006000642A PE2006000642A PE20070165A1 PE 20070165 A1 PE20070165 A1 PE 20070165A1 PE 2006000642 A PE2006000642 A PE 2006000642A PE 2006000642 A PE2006000642 A PE 2006000642A PE 20070165 A1 PE20070165 A1 PE 20070165A1
- Authority
- PE
- Peru
- Prior art keywords
- dry weight
- glitazone
- peptidase
- inhibitor
- base
- Prior art date
Links
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 abstract 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 abstract 2
- UIKDPMGTFQHKLC-UHFFFAOYSA-N 3-(aminomethyl)-2-(2-methylpropyl)-1-oxo-4-phenylisoquinoline-6-carboxamide Chemical compound C12=CC(C(N)=O)=CC=C2C(=O)N(CC(C)C)C(CN)=C1C1=CC=CC=C1 UIKDPMGTFQHKLC-UHFFFAOYSA-N 0.000 abstract 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 abstract 1
- 238000007907 direct compression Methods 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960005095 pioglitazone Drugs 0.000 abstract 1
- 229960004586 rosiglitazone Drugs 0.000 abstract 1
- 229940079832 sodium starch glycolate Drugs 0.000 abstract 1
- 239000008109 sodium starch glycolate Substances 0.000 abstract 1
- 229920003109 sodium starch glycolate Polymers 0.000 abstract 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA EN FORMA DE TABLETAS FORMADAS MEDIANTE COMPRESION DIRECTA QUE COMPRENDE: A) DE 5 A 65% DE UNA BASE DE PESO SECO DE 2 PRINCIPIOS ACTIVOS: i) UN INHIBIDOR DE DIPEPTIDIL-PEPTIDASA IV TALES COMO L-TREO-ISOLEUCIL-TIAZOLIDINA, 3-(AMINO-METIL)-2-ISOBUTIL-1-OXO-4-FENIL-1,2-DIHIDRO-6-ISOQUINOLIN-CARBOXAMIDA, (S)-1-[(3-HIDROXI-1-ADAMANTIL)-AMINO]ACETIL-2-CIANO-PIRROLIDINA, ENTRE OTROS Y ii) UNA GLITAZONA TALES COMO PIOGLITAZONA O ROSIGLITAZONA; B) DE 30 A 95% DE UNA BASE DE PESO SECO DE UN DILUYENTE A BASE DE CELULOSA MICROCRISTALINA; C) DE 0 A 20% DE UNA BASE DE PESO SECO DE UN DESINTEGRANTE A BASE DE LACTOSA; D) DE 0,1 A 10% DE UNA BASE DE PESO SECO DE UN LUBRICANTE A BASE DE GLICOLATO DE ALMIDON DE SODIO. TAMBIEN SE REFIERE A UN POCESO DE PREPARACION DE DICHA COMPOSICION, EN DONDE LA DISTRIBUCION DE TAMANOS DE PARTICULAS EN LA TABLETA ES MENOR A 250 MICRAS
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68973905P | 2005-06-10 | 2005-06-10 | |
| US69052705P | 2005-06-14 | 2005-06-14 | |
| US69081405P | 2005-06-15 | 2005-06-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070165A1 true PE20070165A1 (es) | 2007-03-09 |
Family
ID=37198127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000642A PE20070165A1 (es) | 2005-06-10 | 2006-06-08 | Formulacion de comprension directa que comprende un inhibidor de dipeptidil-peptidasa iv y una glitazona |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20080193529A1 (es) |
| EP (1) | EP1893236A2 (es) |
| JP (1) | JP2008543767A (es) |
| KR (1) | KR20080018257A (es) |
| AR (1) | AR054382A1 (es) |
| AU (2) | AU2006258013A1 (es) |
| BR (1) | BRPI0613567A2 (es) |
| CA (1) | CA2610412A1 (es) |
| GT (1) | GT200600218A (es) |
| MX (1) | MX2007015612A (es) |
| PE (1) | PE20070165A1 (es) |
| SA (1) | SA06270158B1 (es) |
| TW (1) | TW200716175A (es) |
| WO (1) | WO2006135693A2 (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| SG10201809313WA (en) * | 2005-09-29 | 2018-11-29 | Novartis Ag | Formulation comprising metformin and vildagli ptin |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| CN102838599A (zh) | 2006-05-04 | 2012-12-26 | 贝林格尔.英格海姆国际有限公司 | 多晶型 |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| MY147596A (en) | 2007-02-01 | 2012-12-31 | Takeda Pharmaceutical | Solid preparation comprising alogliptin and pioglitazone |
| PE20090597A1 (es) * | 2007-08-16 | 2009-06-06 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido |
| PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| AU2014262269B2 (en) * | 2008-04-03 | 2017-02-02 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
| KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| BRPI0919288A2 (pt) | 2008-09-10 | 2015-12-15 | Boehring Ingelheim Internat Gmbh | teriapia de combinação para tratamento de diabetes e condições relacionadas. |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| KR101054911B1 (ko) | 2008-10-17 | 2011-08-05 | 동아제약주식회사 | 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물 |
| EA022310B1 (ru) | 2008-12-23 | 2015-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Солевые формы органического соединения |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| PL2395983T3 (pl) | 2009-02-13 | 2020-09-07 | Boehringer Ingelheim International Gmbh | Kompozycja farmaceutyczna zawierająca inhibitor sglt2, inhibitor dpp-iv i ewentualnie dalszy środek przeciwcukrzycowy oraz jej zastosowania |
| UY32427A (es) * | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
| SI2459531T1 (sl) * | 2009-07-31 | 2020-02-28 | Krka, D.D., Novo Mesto | Granulat, ki obsega vildagliptin, in postopek njegove priprave |
| NZ599298A (en) | 2009-11-27 | 2014-11-28 | Boehringer Ingelheim Int | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| WO2011138421A1 (en) | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Combination therapy |
| JP5826830B2 (ja) * | 2010-05-05 | 2015-12-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピオグリタゾンとリナグリプチンを含む医薬製剤 |
| NZ603319A (en) | 2010-06-24 | 2015-04-24 | Boehringer Ingelheim Int | Diabetes therapy |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
| CA2841552C (en) | 2011-07-15 | 2020-06-23 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US20130303554A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in sirs and/or sepsis |
| EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
| CN102657626B (zh) * | 2012-05-23 | 2013-07-17 | 重庆康刻尔制药有限公司 | 一种盐酸吡格列酮药物组合片剂 |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| WO2014193528A1 (en) * | 2013-04-29 | 2014-12-04 | Anovel Pharmaceuticals, Llc | Amorphous dosage forms and methods |
| WO2015012365A1 (ja) * | 2013-07-25 | 2015-01-29 | 株式会社 三和化学研究所 | 医薬製剤 |
| ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
| WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
| JP7379189B2 (ja) * | 2020-01-31 | 2023-11-14 | 沢井製薬株式会社 | ビルダグリプチン含有コーティング粒子、ビルダグリプチン含有口腔内崩壊錠、ビルダグリプチン含有コーティング粒子の製造方法及びビルダグリプチン含有口腔内崩壊錠の製造方法 |
| TR202010700A2 (tr) * | 2020-07-06 | 2022-01-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Vi̇ldagli̇pti̇n ve en az bi̇r farmasöti̇k olarak kabul edi̇lebi̇li̇r eksi̇pi̇yan i̇çeren bi̇r formülasyon |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW438587B (en) * | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| DK1248604T4 (da) * | 2000-01-21 | 2012-05-21 | Novartis Ag | Kombinationer indeholdende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler |
| GB0014969D0 (en) * | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
| US7510728B2 (en) * | 2000-10-06 | 2009-03-31 | Takeda Pharmaceutical Company Limited | Solid preparations |
| US6573287B2 (en) * | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
| DE10308355A1 (de) * | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
| US20040186046A1 (en) * | 2003-03-17 | 2004-09-23 | Pfizer Inc | Treatment of type 1 diabetes with PDE5 inhibitors |
| EP1671649B1 (en) * | 2003-10-03 | 2011-11-23 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase IV inhibitors for treating diabetic patients with sulfonylurea secondary failure |
| EP1807066A1 (en) * | 2004-10-25 | 2007-07-18 | Novartis AG | Combination of dpp-iv inhibitor, ppar antidiabetic and metformin |
-
2006
- 2006-05-24 GT GT200600218A patent/GT200600218A/es unknown
- 2006-06-03 SA SA6270158A patent/SA06270158B1/ar unknown
- 2006-06-08 BR BRPI0613567-6A patent/BRPI0613567A2/pt not_active IP Right Cessation
- 2006-06-08 AR ARP060102392A patent/AR054382A1/es unknown
- 2006-06-08 WO PCT/US2006/022336 patent/WO2006135693A2/en not_active Ceased
- 2006-06-08 JP JP2008515929A patent/JP2008543767A/ja active Pending
- 2006-06-08 KR KR1020087000577A patent/KR20080018257A/ko not_active Ceased
- 2006-06-08 MX MX2007015612A patent/MX2007015612A/es unknown
- 2006-06-08 EP EP06772588A patent/EP1893236A2/en not_active Withdrawn
- 2006-06-08 AU AU2006258013A patent/AU2006258013A1/en not_active Abandoned
- 2006-06-08 US US11/916,490 patent/US20080193529A1/en not_active Abandoned
- 2006-06-08 CA CA002610412A patent/CA2610412A1/en not_active Abandoned
- 2006-06-08 PE PE2006000642A patent/PE20070165A1/es not_active Application Discontinuation
- 2006-06-09 TW TW095120636A patent/TW200716175A/zh unknown
-
2010
- 2010-08-24 AU AU2010212516A patent/AU2010212516A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| GT200600218A (es) | 2007-03-28 |
| KR20080018257A (ko) | 2008-02-27 |
| US20080193529A1 (en) | 2008-08-14 |
| JP2008543767A (ja) | 2008-12-04 |
| MX2007015612A (es) | 2008-02-25 |
| CA2610412A1 (en) | 2006-12-21 |
| WO2006135693A3 (en) | 2007-02-15 |
| SA06270158B1 (ar) | 2010-10-23 |
| TW200716175A (en) | 2007-05-01 |
| AR054382A1 (es) | 2007-06-20 |
| AU2006258013A1 (en) | 2006-12-21 |
| AU2010212516A1 (en) | 2010-09-16 |
| WO2006135693A2 (en) | 2006-12-21 |
| EP1893236A2 (en) | 2008-03-05 |
| BRPI0613567A2 (pt) | 2011-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20050686A1 (es) | Formulacion para compresion directa y proceso | |
| AR052878A1 (es) | Formulacion de compresion directa y proceso | |
| AR043315A1 (es) | Composiciones detergentes | |
| RU2010128019A (ru) | Пероральная диспергируемая таблетка | |
| PH12013502277A1 (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4 methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids | |
| NZ594022A (en) | Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof | |
| PE20121442A1 (es) | Derivados de oxindol sustituido y composiciones farmaceuticas que los comprenden | |
| PE20140163A1 (es) | Composiciones terapeuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato | |
| AR054382A1 (es) | Formulacion de compresion directa de un inhibidor de dipeptidil-peptidasa iv y una glitazona y proceso | |
| AR074739A1 (es) | Comprimidos de capecitabina de disgregacion rapida | |
| RU2008135718A (ru) | Композиции клопидогреля бисульфата | |
| CR20120061A (es) | Tableta | |
| RU2009116832A (ru) | Композиция, включающая арбидол в составе фосфолипидных наночастиц | |
| JP2008536020A5 (es) | ||
| CY1109865T1 (el) | Συνθεσεις βαλσαρτανης | |
| CO6150180A2 (es) | Sales de bencimidazolil-piridil-eteres y formulaciones de las mismas | |
| AR059045A1 (es) | Composicion farmaceutica y proceso | |
| PE20110119A1 (es) | Asociacion entre ferroquina y artesunato para el tratamiento del paludismo | |
| EA201071309A1 (ru) | Твердая фармацевтическая композиция | |
| PE20081801A1 (es) | Formas solidas de un inhibidor de cinasa raf | |
| UA89684C2 (ru) | Двухслойная фармацевтическая дозированная форма с модифицированным высвобождением нимесулида | |
| ES2605017T3 (es) | Preparación para prevenir o tratar afecciones por carencia de calcio en mamíferos | |
| EA201001108A1 (ru) | Диспергируемые во рту таблетки, содержащие основание эсциталопрама, и способ их получения | |
| IS1935B (is) | Fósínópríl lyfjasamsetning | |
| PL1868631T3 (pl) | Zastosowanie związków indukujących syntezę białek SIRT przy lub dla otrzymywania kompozycji kosmetycznej lub farmaceutycznej |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |